BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IIEP UBA-CONICET - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://economicas.uba.ar/iiep
X-WR-CALDESC:Eventos para IIEP UBA-CONICET
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Argentina/Buenos_Aires
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0300
TZNAME:-03
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Argentina/Buenos_Aires:20260422T130000
DTEND;TZID=America/Argentina/Buenos_Aires:20260422T143000
DTSTAMP:20260417T164427
CREATED:20260407T144006Z
LAST-MODIFIED:20260409T145004Z
UID:22713-1776862800-1776868200@economicas.uba.ar
SUMMARY:Seminario de investigación | The Political Economy of Pharmaceutical Patent Examination: The Case of Argentina
DESCRIPTION:Expositor | Ken Shadlen | LSE \nPharmaceutical patenting is new in many developing countries\, required by the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). In complying with this new international obligation\, some countries introduced measures to reduce the grant of patents on alternative forms of existing drugs\, i.e. “secondary patents\,” fearing that such patents can delay generic competition after the expiration of patents on drugs’ main compounds\, i.e. “primary patents.” Yet previous empirical research on measures to reduce the grant of secondary patents in developing countries has reported these interventions to have minimal effectiveness. \nThis mixed-methods paper analyzes Argentina’s 2012 pharmaceutical patent examination guidelines. Quantitative analyses\, based on a dataset of all pharmaceutical patent applications filed in Argentina over a 20 year period\, with applications coded as “primary” and “secondary\,” demonstrate that the guidelines reduced the grant of secondary patents in Argentina. Qualitative analyses of state-society interaction in the process of patent examination\, based on research conducted in Argentina throughout the period that the guidelines were in effect\, provide a political economy explanation for effectiveness.  The political economy analyses also explain the 2012 guidelines’ long persistence\, despite intense opposition from the international pharmaceutical industry and foreign governments\, and their eventual removal in 2026. \n  \nLugar | FCE-UBA | Aula Olivera
URL:https://economicas.uba.ar/iiep/eventos/the-political-economy-of-pharmaceutical-patent-examination-the-case-of-argentina/
CATEGORIES:Destacada,Seminario IIEP
END:VEVENT
END:VCALENDAR